about
Cancer as an evolutionary and ecological processImmunologically silent cancer clone transmission from mother to offspringLife history trade-offs in cancer evolutionDifferent regulation of MHC class I antigen processing components in human tumors.Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinomaFOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy.DNA vaccines: developing new strategies against cancer.CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance.An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer.Adaptive immunity does not strongly suppress spontaneous tumors in a Sleeping Beauty model of cancer.In vivo tumor secretion probing via ultrafiltration and tissue chamber: implication for anti-cancer drugs targeting secretome.An evolutionary explanation for the perturbation of the dynamics of metastatic tumors induced by surgery and acute inflammation.Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.Trichosanthin enhances anti-tumor immune response in a murine Lewis lung cancer model by boosting the interaction between TSLC1 and CRTAM.DNA vaccination: using the patient's immune system to overcome cancerImmunotherapy in nonmelanoma skin cancer.Pembrolizumab: a novel antiprogrammed death 1 (PD-1) monoclonal antibody for treatment of metastatic melanoma.Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer.Sodium valproate sensitizes non-small lung cancer A549 cells to γδ T-cell-mediated killing through upregulating the expression of MICA.Characterization of small spheres derived from various solid tumor cell lines: are they suitable targets for T cells?Methylation-specific ligation detection reaction (msLDR): a new approach for multiplex evaluation of methylation patterns.Autologous CTL response against cancer stem-like cells/cancer-initiating cells of bone malignant fibrous histiocytoma.Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.Anti-tumor immunostimulatory effect of heat-killed tumor cells.Cancer vaccine development: designing tumor cells for greater immunogenicity.A study of tumour growth based on stoichiometric principles: a continuous model and its discrete analogue.Classifying the evolutionary and ecological features of neoplasms.Innate immunity protein Tag7 (PGRP-S) activates lymphocytes capable of Fasl-Fas-dependent contact killing of virus-infected cells.Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer.CD3+ CD8+ NKG2D+ T Lymphocytes Induce Apoptosis and Necroptosis in HLA-Negative Cells via FasL-Fas Interaction.The amount of surface HLA-I on T lymphocytes decreases in breast infiltrating ductal carcinoma patients.Immunization with a HSP65-HER2 fusion peptide selectively eliminates HER2(+) B16 melanoma cells in a xenograft tumor mouse model.Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies.Tag7 (PGLYRP1) Can Induce an Emergence of the CD3+CD4+CD25+CD127+ Cells with Antitumor Activity.
P2860
Q22122026-38159BA9-67C1-43C7-AEB1-9DEFAB3C346AQ24650876-B73B8D29-3966-47B4-9035-4C8F751D694CQ28657962-F238D52A-61DD-4D60-8F43-0E4A22889076Q30319116-CD41AD88-CD21-4143-8B54-3A168E3B3023Q33317415-C3360750-B45B-410A-9167-BC7066EE8738Q33320890-CF078F16-6F6D-4418-AD56-8FAD4BB43810Q33756622-61BB46AB-2AD2-403D-BA18-EC32CF56C463Q35600651-DF33CA0F-890C-434F-82FD-361D42C712C2Q36085118-C9EB01DB-E196-4523-98B7-CCA01955D5BCQ36754562-B9A3BE5C-F5AA-4A14-A2AF-616BF8101DA1Q37090386-E36BF0B4-C9DE-48B5-BDEE-F3636F15CA5FQ37129834-10BF64C2-5A35-4595-9371-8F0F81467079Q37461075-E00D0E2D-3CB6-4624-BACC-7C29E14C9B93Q37728221-3F564AD6-475F-4B85-8A46-9FDF45C3B36AQ37825422-2BCC3AED-0774-4091-9DAA-2F1F24FFD796Q38014084-F4099A15-C0A7-416B-AD62-5B4687E22904Q38540340-7C646427-4051-4F58-92EC-D73D434ECB93Q38590722-C4032F8F-04C4-45F4-A4E0-0D833EBD9BDAQ39114878-09040E63-21E6-4F2B-B93F-F36E00516E65Q39177284-FF4CEFBD-DA32-42B2-AAE6-5E84F33ADBF3Q39481853-3B71BD3D-0735-4C59-BCBB-919574C44FC2Q39553499-5FF310F8-00CD-4D70-B614-A76DAC77D423Q39767227-E183AF5F-2516-4469-B1BA-F2FCEE6A0463Q40008171-DD811EA4-B20E-4E55-B544-11A873D5DFF7Q42384053-EBD44832-4791-41C1-B0B8-4FEDE97EB982Q42976065-32588291-9448-4442-A371-0590D3638868Q45067426-717EC385-4BC0-48B4-8C2B-1F60697497B6Q45325513-295EF4EC-2215-4A47-B7E7-A339E2DB24F3Q48097366-8485FB1A-4F13-44CD-BC53-EDF9B8DF4289Q48127699-5132E0F6-176A-49D9-8848-4AAF381C8C5AQ51450535-6BB1E0FA-123D-4884-8277-F2221EB1873DQ54478329-ADD4B394-63C1-45CB-8E4B-BFAC12F1447FQ55085319-91EBB258-72DB-49AB-BD3F-AC5710F3FD74Q55285823-E00DBDD8-72C3-4A76-8C48-8FE6801473F7
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
name
Strategies of tumor immune evasion.
@ast
Strategies of tumor immune evasion.
@en
Strategies of tumor immune evasion.
@en-gb
type
label
Strategies of tumor immune evasion.
@ast
Strategies of tumor immune evasion.
@en
Strategies of tumor immune evasion.
@en-gb
prefLabel
Strategies of tumor immune evasion.
@ast
Strategies of tumor immune evasion.
@en
Strategies of tumor immune evasion.
@en-gb
P2860
P1433
P1476
Strategies of tumor immune evasion.
@en
P2093
Barbara Seliger
P2860
P304
P356
10.2165/00063030-200519060-00002
P577
2005-01-01T00:00:00Z
P5875
P6179
1006795002